Clinical trial shows promise for increasing lung transplant patients' life expectancy
from American Association for Thoracic Surgery via EurekAlert!
A new study, presented May 5 at the American Association for Thoracic Surgery's 99th Annual Meeting, shows that a potential treatment for ischemia- reperfusion injury is safe for humans. Building upon three decades of preclinical animal studies, this NIH-funded trial demonstrated, for the first time, the safety of Regadenoson (an adenosine 2A receptor agonist) in human lung transplant patients.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063